Comment on “Lack of Association Found between Helicobacter pylori Infection and Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Retrospective Study”

الملخص EN

We have read with great interest the paper written by Feng Xiong et al.

“Lack of Association Found between Helicobacter pylori Infection and Diarrhea-Predominant Irritable Bowel Syndrome: A Multicenter Retrospective Study” [1].

From the beginning, possible association between H.

pylori infection and diarrhea-predominant irritable bowel syndrome (IBS-D) was a challenging topic among clinicians [2].

In this paper, authors concluded that no significant correlation between H.

pylori infection and IBS-D was reported.

Moreover, IBS-D patients may not benefit from H.

pylori eradication.

Apart from being an interesting study, there is a short list of critical points to draw a better conclusion within such multicenter studies worldwide.

(1) Sample size is mainly lacking in this study.

Relatively high rate of treatment efficacy observed in H.

pylori infected group can be bound to the low number of investigated individuals.

(2) Lack of long-term follow-up in this study is leading to incorrect conclusion regarding relieving bloating symptoms.

Moreover, insufficient study design for treatment of the bacterium was another pitfall causing not strong conclusion.

According to the current findings, authors concluded that IBS-D patients do not benefit from H.

pylori eradication.

As a note, determination of successful H.

pylori eradication is not clearly described and validated in this study.

Also, we need a long-term follow-up (at least 6 months) to confirm primary conclusion drawn by the authors.

(3) With regard to the current findings, to be honest, it seems that we have a lack of better evidence rather than lack of association.

In conclusion, we agree with Xiong et al., if proven in further studies, about the underlying mechanisms determining H.

pylori role in IBS.

Finally, the understanding of the H.

pylori-host interaction in IBS subjects may open the insight into the development of new therapeutic interventions to manage H.

pylori associated extra-digestive disease.